Pleven

• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended recruitment
  2023-509300-14-00 5 2024-10-31 Severe hypertriglyceridemia (SHTG)
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended recruitment
  2023-507261-25-00 5 2024-10-03 Nonmuscle Invasive Bladder Cancer
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended recruitment
  2024-512747-23-00 5 2024-07-30 Transfusion-Dependent Alpha- or Beta-Thalassemia
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV … Ended recruitment
  2023-507456-69-00 4 2024-04-25 Atopic Dermatitis
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended recruitment
  2022-502105-15-00 4 2023-10-20 Systemic lupus erythematosus
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation

Showing 145–168 of 284 trials